Revenue + Forward P/E
Immunovant, Inc. (IMVT) quarterly revenue and forward P/E
RevenueRevenue (est)Forward P/E
Valuation
Market cap
$8.70B
Enterprise value
$7.11B
P/E ratio (TTM)
-14.04x
P/S ratio (TTM)
0.00x
P/B ratio
9.32x
EV/Sales
0.00x
EV/EBITDA
-14.08x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$0
Gross profit (TTM)
$-409000
Operating income (TTM)
$-532.90M
EBITDA (TTM)
$-504.98M
Net income (TTM)
$-505.61M
Free cash flow (TTM)
$-407.32M
Margins & returns
Gross margin
0.00%
Operating margin
0.00%
Profit margin
0.00%
Return on equity
-68.16%
Return on assets
-52.83%
Per-share metrics
EPS (TTM)
-$2.48
Dividend yield
0.00%
Beta
0.77
Capital structure
Cash & equivalents
$902.11M
Total debt
$72000
Net debt
$-902.04M
Shares outstanding
206.40M
Financial health
Current ratio
9.09
Debt / equity
0.00
Debt / assets
0.00
Interest coverage
-
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.14T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.85B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $441.87B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $364.76B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $333.01B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $8.70B | -14.04x | 0.00x | -14.08x | - |